LifeStance Health Group (LFST) Financials

$6.82 -0.03 (-0.44%)

Closing price 04/15/2025 04:00 PM Eastern

Extended Trading

$6.82 0.00 (-0.07%)

As of 04/15/2025 04:20 PM Eastern

Annual Income Statements for LifeStance Health Group

This table shows LifeStance Health Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-59	-344	-216	-186	-57
Consolidated Net Income / (Loss)	5.67	-307	-216	-186	-57
Net Income / (Loss) Continuing Operations	5.67	-307	-216	-186	-57
Total Pre-Tax Income	7.88	-333	-233	-207	-58
Total Operating Income	15	-286	-210	-189	-32
Total Gross Profit	213	668	860	1,056	1,251
Total Revenue	213	668	860	1,056	1,251
Operating Revenue	213	668	860	1,056	1,251
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	197	954	1,070	1,245	1,283
Selling, General & Admin Expense	191	900	378	411	363
Depreciation Expense	6.10	54	69	80	71
Other Operating Expenses / (Income)	-	-	623	754	849
Total Other Income / (Expense), net	-7.37	-47	-23	-17	-26
Interest Expense	5.41	39	20	21	27
Other Income / (Expense), net	-1.96	-7.84	-2.63	3.77	0.54
Income Tax Expense	2.21	-26	-17	-20	-0.17
Weighted Average Basic Shares Outstanding	0.00	327.52K	355.28M	367.46M	379.15M
Weighted Average Diluted Shares Outstanding	0.00	327.52K	355.28M	367.46M	379.15M
Weighted Average Basic & Diluted Shares Outstanding	0.00	327.52K	376.37M	380.69M	384.55M

This table shows LifeStance Health Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-38	-47	-34	-45	-62	-45	-21	-23	-5.96	-7.11
Consolidated Net Income / (Loss)	-38	-47	-34	-45	-62	-45	-21	-23	-5.96	-7.11
Net Income / (Loss) Continuing Operations	-38	-47	-34	-45	-62	-45	-21	-23	-5.96	-7.11
Total Pre-Tax Income	-42	-54	-38	-52	-78	-38	-21	-23	-5.38	-8.88
Total Operating Income	-39	-46	-34	-48	-74	-32	-17	-16	0.05	1.06
Total Gross Profit	218	229	253	260	263	281	300	312	313	325
Total Revenue	218	229	253	260	263	281	300	312	313	325
Operating Revenue	218	229	253	260	263	281	300	312	313	325
Total Operating Expenses	256	275	287	308	337	313	317	328	313	324
Selling, General & Admin Expense	239	-366	268	288	318	-463	295	310	298	-539
Depreciation Expense	18	19	19	20	20	22	23	19	15	15
Total Other Income / (Expense), net	-3.37	-7.70	-4.19	-3.61	-3.61	-6.05	-3.96	-6.67	-5.43	-9.94
Interest Expense	4.19	5.17	5.09	5.12	5.48	5.53	5.90	5.82	5.41	9.40
Other Income / (Expense), net	0.82	-2.54	0.91	1.51	1.87	-0.51	1.94	-0.85	-0.02	-0.54
Income Tax Expense	-4.35	-7.06	-4.04	-6.54	-16	6.64	0.36	0.66	0.58	-1.76
Weighted Average Basic Shares Outstanding	357.52K	355.28M	360.90M	363.16M	372.48M	367.46M	376.33M	379.43M	380.36M	379.15M
Weighted Average Diluted Shares Outstanding	357.52K	355.28M	360.90M	363.16M	372.48M	367.46M	376.33M	379.43M	380.36M	379.15M
Weighted Average Basic & Diluted Shares Outstanding	375.99M	376.37M	376.76M	378.01M	378.61M	380.69M	382.29M	382.62M	382.64M	384.55M

This table details how cash moves in and out of LifeStance Health Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2021	2022	2023	2024
Net Change in Cash & Equivalents	-7.86	129	-39	-30	76
Net Cash From Operating Activities	17	9.42	53	-17	107
Net Cash From Continuing Operating Activities	17	9.42	53	-17	107
Net Income / (Loss) Continuing Operations	5.67	-307	-216	-186	-57
Consolidated Net Income / (Loss)	5.67	-307	-216	-186	-57
Depreciation Expense	6.10	54	69	80	71
Amortization Expense	0.71	1.80	1.95	2.10	1.67
Non-Cash Adjustments To Reconcile Net Income	-0.18	285	231	142	120
Changes in Operating Assets and Liabilities, net	4.75	-25	-34	-56	-28
Net Cash From Investing Activities	-73	-194	-139	-60	-22
Net Cash From Continuing Investing Activities	-73	-194	-139	-60	-22
Purchase of Property, Plant & Equipment	-14	-94	-79	-41	-22
Acquisitions	-59	-100	-60	-20	0.00
Net Cash From Financing Activities	48	314	47	47	-9.95
Net Cash From Continuing Financing Activities	48	314	47	47	-9.95
Repayment of Debt	-2.45	-323	-197	-2.66	-291
Issuance of Debt	56	99	257	58	288
Other Financing Activities, net	-5.02	-12	-13	-7.67	-6.44
Cash Interest Paid	4.58	22	14	21	25
Cash Income Taxes Paid	0.25	1.09	2.24	0.08	0.06

This table details how cash moves in and out of LifeStance Health Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-6.35	18	-40	11	-37	36	-29	38	16	52
Net Cash From Operating Activities	5.73	36	-7.89	-0.43	-25	17	-22	44	23	62
Net Cash From Continuing Operating Activities	5.73	36	-7.89	-0.43	-25	17	-22	44	23	62
Net Income / (Loss) Continuing Operations	-38	-47	-34	-45	-62	-45	-21	-23	-5.96	-7.11
Consolidated Net Income / (Loss)	-38	-47	-34	-45	-62	-45	-21	-23	-5.96	-7.11
Depreciation Expense	18	19	19	20	20	22	23	19	15	15
Amortization Expense	0.60	0.60	0.55	0.53	0.52	0.51	0.42	0.42	0.42	0.40
Non-Cash Adjustments To Reconcile Net Income	34	76	33	44	32	33	28	35	26	32
Changes in Operating Assets and Liabilities, net	-8.74	-13	-26	-19	-16	5.90	-52	14	-12	22
Net Cash From Investing Activities	-20	-30	-28	-12	-9.80	-11	-5.10	-5.11	-5.05	-6.30
Net Cash From Continuing Investing Activities	-20	-30	-28	-12	-9.80	-11	-5.10	-5.11	-5.05	-6.30
Purchase of Property, Plant & Equipment	-15	-10	-7.73	-12	-9.80	-11	-5.10	-5.11	-5.05	-6.30
Net Cash From Financing Activities	8.19	13	-4.89	23	-1.85	31	-2.43	-1.43	-2.03	-4.06
Net Cash From Continuing Financing Activities	8.19	13	-4.89	23	-1.85	31	-2.43	-1.43	-2.03	-4.06
Repayment of Debt	-0.08	-6.54	-0.59	-0.78	-0.65	-0.65	-0.73	-0.73	-0.73	-289
Issuance of Debt	9.47	20	-	-	-	33	-	-	-	288
Other Financing Activities, net	-1.20	-0.65	-4.30	-0.90	-1.20	-1.27	-1.70	-0.70	-1.29	-2.75
Cash Interest Paid	4.59	4.85	5.06	4.77	5.59	5.62	6.27	6.36	6.40	5.97
Cash Income Taxes Paid	0.92	0.46	-0.01	0.33	0.10	-0.34	-0.25	0.10	0.21	-0.00

This table presents LifeStance Health Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Total Assets	1,570	1,927	2,174	2,110	2,118
Total Current Assets	76	267	233	226	313
Cash & Equivalents	19	148	109	79	155
Accounts Receivable	44	76	101	125	132
Prepaid Expenses	14	42	24	22	26
Plant, Property, & Equipment, net	59	152	194	188	166
Total Noncurrent Assets	1,434	1,508	1,746	1,696	1,640
Goodwill	1,099	1,205	1,273	1,293	1,293
Intangible Assets	333	300	263	221	191
Other Noncurrent Operating Assets	2.65	3.45	210	182	156
Total Liabilities & Shareholders' Equity	1,570	1,927	2,174	2,110	2,118
Total Liabilities	537	382	655	681	672
Total Current Liabilities	76	117	176	203	229
Short-Term Debt	11	14	16	8.17	0.00
Accounts Payable	7.69	14	12	7.05	7.24
Accrued Expenses	15	27	30	35	47
Current Employee Benefit Liabilities	38	60	76	102	117
Other Current Liabilities	4.96	1.97	42	50	57
Total Noncurrent Liabilities	461	265	479	478	443
Long-Term Debt	363	157	225	280	280
Noncurrent Deferred & Payable Income Tax Liabilities	81	54	39	16	14
Other Noncurrent Operating Liabilities	17	54	215	182	149
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	998	1,545	1,519	1,429	1,446
Total Preferred & Common Equity	998	1,545	1,519	1,429	1,446
Preferred Stock	0.00	0.00	0.00	0.00	0.00
Total Common Equity	998	1,545	1,519	1,429	1,446
Common Stock	1,011	1,902	2,088	2,187	2,264
Retained Earnings	-13	-357	-573	-761	-818
Accumulated Other Comprehensive Income / (Loss)	-	0.00	3.27	2.30	0.93

This table presents LifeStance Health Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,980	2,159	2,171	2,175	2,106	2,119	2,108
Total Current Assets	253	213	238	264	244	278	287
Cash & Equivalents	90	68	80	43	49	87	103
Accounts Receivable	113	118	122	150	176	167	158
Prepaid Expenses	49	26	36	72	19	24	26
Plant, Property, & Equipment, net	193	194	193	190	182	176	170
Total Noncurrent Assets	1,534	1,753	1,740	1,721	1,680	1,666	1,651
Goodwill	1,250	1,294	1,294	1,293	1,293	1,293	1,293
Intangible Assets	272	254	244	234	209	200	195
Other Noncurrent Operating Assets	11	205	203	194	178	172	162
Total Liabilities & Shareholders' Equity	1,980	2,159	2,171	2,175	2,106	2,119	2,108
Total Liabilities	448	653	676	720	677	689	671
Total Current Liabilities	112	181	181	241	207	228	218
Short-Term Debt	11	13	11	8.96	4.45	3.81	2.50
Accounts Payable	7.95	7.71	8.04	10	12	9.97	7.28
Accrued Expenses	29	32	34	91	37	38	43
Current Employee Benefit Liabilities	62	84	81	84	100	123	112
Other Current Liabilities	2.63	44	47	47	53	53	53
Total Noncurrent Liabilities	336	472	495	479	470	462	453
Long-Term Debt	212	225	249	248	280	279	279
Noncurrent Deferred & Payable Income Tax Liabilities	55	38	38	38	16	16	15
Other Noncurrent Operating Liabilities	68	210	208	192	174	166	159
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,532	1,505	1,495	1,455	1,429	1,430	1,437
Total Preferred & Common Equity	1,532	1,505	1,495	1,455	1,429	1,430	1,437
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,532	1,505	1,495	1,455	1,429	1,430	1,437
Common Stock	2,054	2,112	2,145	2,167	2,208	2,233	2,247
Retained Earnings	-526	-609	-654	-716	-782	-805	-811
Accumulated Other Comprehensive Income / (Loss)	3.19	2.00	4.15	4.38	2.89	2.64	0.77

This table displays calculated financial ratios and metrics derived from LifeStance Health Group's official financial filings.

Metric	2019	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	0.00%	28.77%	22.82%	18.50%
EBITDA Growth	0.00%	0.00%	40.55%	27.41%	140.40%
EBIT Growth	0.00%	0.00%	27.67%	12.89%	83.23%
NOPAT Growth	0.00%	0.00%	26.60%	10.01%	83.29%
Net Income Growth	0.00%	0.00%	29.83%	13.59%	69.16%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	0.00%	0.00%	460.39%	-131.98%	735.28%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	47.79%	137.47%
Invested Capital Growth	0.00%	0.00%	5.26%	-0.76%	-4.09%
Revenue Q/Q Growth	0.00%	0.00%	4.80%	5.10%	3.72%
EBITDA Q/Q Growth	0.00%	0.00%	34.13%	15.60%	161.46%
EBIT Q/Q Growth	0.00%	0.00%	24.63%	7.84%	51.73%
NOPAT Q/Q Growth	0.00%	0.00%	24.38%	6.77%	51.32%
Net Income Q/Q Growth	0.00%	0.00%	23.01%	0.90%	39.72%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	11.12%	-854.09%	73.73%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	18.86%	442.27%
Invested Capital Q/Q Growth	0.00%	0.00%	-0.78%	-1.87%	-2.76%
Profitability Metrics	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	9.45%	-35.69%	-16.48%	-9.74%	3.32%
Operating Margin	7.17%	-42.90%	-24.45%	-17.92%	-2.53%
EBIT Margin	6.25%	-44.07%	-24.76%	-17.56%	-2.48%
Profit (Net Income) Margin	2.67%	-46.02%	-25.08%	-17.64%	-4.59%
Tax Burden Percent	71.99%	92.22%	92.62%	90.16%	99.70%
Interest Burden Percent	59.28%	113.23%	109.36%	111.45%	185.38%
Effective Tax Rate	28.01%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-12.78%	-9.14%	-8.05%	-1.38%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-466.84%	-96.97%	-39.55%	-22.47%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-7.10%	-4.93%	-4.59%	-2.62%
Return on Equity (ROE)	0.00%	-19.88%	-14.07%	-12.64%	-4.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-14.27%	-7.29%	2.80%
Operating Return on Assets (OROA)	0.00%	-16.83%	-10.38%	-8.65%	-1.47%
Return on Assets (ROA)	0.00%	-17.57%	-10.51%	-8.70%	-2.72%
Return on Common Equity (ROCE)	0.00%	-19.61%	-14.07%	-12.64%	-4.00%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-19.88%	-14.19%	-13.04%	-3.97%
Net Operating Profit after Tax (NOPAT)	11	-200	-147	-132	-22
NOPAT Margin	5.16%	-30.03%	-17.12%	-12.54%	-1.77%
Net Nonoperating Expense Percent (NNEP)	0.00%	454.06%	87.83%	31.51%	21.09%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-8.36%	-7.71%	-1.28%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	89.96%	134.79%	43.98%	38.91%	29.02%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	92.83%	142.90%	124.45%	117.92%	102.53%
Earnings before Interest and Taxes (EBIT)	13	-294	-213	-185	-31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	20	-238	-142	-103	42
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.31	1.22	2.07	1.95
Price to Tangible Book Value (P/TBV)	0.00	88.76	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.39	5.34	2.16	2.81	2.25
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	2.29	1.21	1.94	1.87
Enterprise Value to Revenue (EV/Rev)	0.00	5.37	2.31	3.01	2.35
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	70.91
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	380.62	37.69	0.00	27.46
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	65.56
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.11	0.16	0.20	0.19
Long-Term Debt to Equity	0.00	0.10	0.15	0.20	0.19
Financial Leverage	0.00	0.02	0.05	0.12	0.12
Leverage Ratio	0.00	1.36	1.34	1.45	1.47
Compound Leverage Factor	0.00	1.54	1.46	1.62	2.73
Debt to Total Capital	0.00%	9.99%	13.69%	16.80%	16.21%
Short-Term Debt to Total Capital	0.00%	0.82%	0.90%	0.48%	0.00%
Long-Term Debt to Total Capital	0.00%	9.17%	12.79%	16.32%	16.21%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	90.01%	86.31%	83.20%	83.79%
Debt to EBITDA	0.00	-0.72	-1.70	-2.81	6.74
Net Debt to EBITDA	0.00	-0.10	-0.93	-2.04	3.01
Long-Term Debt to EBITDA	0.00	-0.66	-1.59	-2.73	6.74
Debt to NOPAT	0.00	-0.86	-1.64	-2.18	-12.64
Net Debt to NOPAT	0.00	-0.12	-0.90	-1.58	-5.66
Long-Term Debt to NOPAT	0.00	-0.79	-1.53	-2.12	-12.64
Altman Z-Score	0.00	5.27	1.44	2.33	2.57
Noncontrolling Interest Sharing Ratio	0.00%	1.36%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.00	2.28	1.33	1.11	1.37
Quick Ratio	0.00	1.92	1.19	1.01	1.25
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.00	-230	-120	45
Operating Cash Flow to CapEx	119.10%	9.97%	66.61%	-41.67%	497.36%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-11.52	-5.65	1.69
Operating Cash Flow to Interest Expense	3.15	0.24	2.65	-0.80	4.04
Operating Cash Flow Less CapEx to Interest Expense	0.51	-2.19	-1.33	-2.71	3.23
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	0.38	0.42	0.49	0.59
Accounts Receivable Turnover	0.00	11.15	9.72	9.33	9.73
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	6.31	4.96	5.52	7.06
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	32.75	37.57	39.12	37.52
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	32.75	37.57	39.12	37.52
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	0.00	1,569	1,651	1,639	1,572
Invested Capital Turnover	0.00	0.43	0.53	0.64	0.78
Increase / (Decrease) in Invested Capital	0.00	0.00	83	-12	-67
Enterprise Value (EV)	0.00	3,585	1,990	3,174	2,945
Market Capitalization	720	3,562	1,857	2,964	2,820
Book Value per Share	$0.00	$4.13	$4.04	$3.77	$3.78
Tangible Book Value per Share	$0.00	$0.11	($0.05)	($0.23)	($0.10)
Total Capital	0.00	1,717	1,760	1,717	1,726
Total Debt	0.00	172	241	288	280
Total Long-Term Debt	0.00	157	225	280	280
Net Debt	0.00	24	132	210	125
Capital Expenditures (CapEx)	14	94	79	41	22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	16	-36	-48	-71
Debt-free Net Working Capital (DFNWC)	0.00	164	73	31	84
Net Working Capital (NWC)	0.00	150	57	23	84
Net Nonoperating Expense (NNE)	5.30	107	68	54	35
Net Nonoperating Obligations (NNO)	0.00	24	132	210	125
Total Depreciation and Amortization (D&A)	6.80	56	71	83	73
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	2.38%	-4.13%	-4.53%	-5.67%
Debt-free Net Working Capital to Revenue	0.00%	24.55%	8.50%	2.94%	6.68%
Net Working Capital to Revenue	0.00%	22.44%	6.66%	2.17%	6.68%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	0.00	374.27M	355.28K	367.46K	379.15M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	0.00	374.27M	376.37M	367.46K	379.15M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	327.52K	376.37M	380.69M	384.55M
Normalized Net Operating Profit after Tax (NOPAT)	11	-200	-147	-132	-22
Normalized NOPAT Margin	5.16%	-30.03%	-17.12%	-12.54%	-1.77%
Pre Tax Income Margin	3.71%	-49.90%	-27.08%	-19.57%	-4.61%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	2.46	-7.56	-10.68	-8.74	-1.17
NOPAT to Interest Expense	2.03	-5.15	-7.38	-6.24	-0.83
EBIT Less CapEx to Interest Expense	-0.19	-9.99	-14.66	-10.64	-1.98
NOPAT Less CapEx to Interest Expense	-0.62	-7.58	-11.36	-8.15	-1.65
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from LifeStance Health Group's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	25.15%	20.72%	24.37%	23.89%	20.84%	22.34%	18.94%	20.32%	18.95%	15.99%
EBITDA Growth	82.49%	71.63%	72.63%	38.25%	-168.07%	65.40%	160.12%	108.28%	129.73%	255.03%
EBIT Growth	69.76%	58.89%	49.38%	22.70%	-90.68%	32.48%	55.31%	64.18%	100.04%	101.59%
NOPAT Growth	68.85%	59.55%	47.43%	19.94%	-91.45%	29.86%	50.81%	67.06%	100.06%	103.28%
Net Income Growth	68.57%	58.00%	45.06%	33.83%	-62.69%	3.64%	38.39%	48.82%	90.33%	84.18%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	140.33%	17.25%	-338.51%	-105.54%	-542.50%	-53.24%	-176.78%	10,252.07%	189.62%	271.04%
Free Cash Flow Firm Growth	88.25%	0.00%	95.24%	75.70%	69.09%	91.20%	99.05%	160.27%	193.04%	771.75%
Invested Capital Growth	10.62%	5.26%	3.42%	1.67%	0.35%	-0.76%	-0.66%	-2.88%	-3.22%	-4.09%
Revenue Q/Q Growth	3.83%	5.42%	10.13%	2.77%	1.28%	6.74%	7.07%	3.96%	0.13%	4.08%
EBITDA Q/Q Growth	55.08%	-48.83%	53.32%	-97.83%	-95.03%	80.79%	181.10%	-72.76%	600.54%	0.17%
EBIT Q/Q Growth	37.34%	-27.71%	31.65%	-41.32%	-54.56%	54.78%	54.76%	-13.26%	100.18%	1,577.42%
NOPAT Q/Q Growth	35.77%	-18.47%	25.90%	-42.00%	-53.59%	56.60%	48.03%	4.92%	100.29%	2,153.19%
Net Income Q/Q Growth	44.92%	-23.26%	26.61%	-32.81%	-35.41%	26.99%	53.08%	-10.33%	74.41%	-19.39%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-26.85%	526.84%	-121.97%	94.50%	-5,742.17%	166.24%	-230.03%	301.76%	-48.43%	174.25%
Free Cash Flow Firm Q/Q Growth	26.06%	38.65%	30.86%	22.53%	5.94%	82.54%	92.50%	4,990.03%	45.20%	26.07%
Invested Capital Q/Q Growth	1.04%	-0.78%	1.44%	-0.02%	-0.28%	-1.87%	1.54%	-2.26%	-0.63%	-2.76%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-8.98%	-12.67%	-5.37%	-10.34%	-19.91%	-3.58%	2.72%	0.71%	4.98%	4.79%
Operating Margin	-17.85%	-20.06%	-13.50%	-18.65%	-28.28%	-11.50%	-5.58%	-5.11%	0.02%	0.33%
EBIT Margin	-17.47%	-21.17%	-13.14%	-18.07%	-27.57%	-11.68%	-4.94%	-5.38%	0.01%	0.16%
Profit (Net Income) Margin	-17.40%	-20.34%	-13.56%	-17.52%	-23.42%	-16.02%	-7.02%	-7.45%	-1.90%	-2.19%
Tax Burden Percent	89.69%	86.86%	89.45%	87.42%	78.99%	117.34%	101.75%	102.90%	110.68%	80.13%
Interest Burden Percent	111.02%	110.64%	115.34%	110.91%	107.56%	116.87%	139.80%	134.66%	-17,361.29%	-1,706.92%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-6.47%	-7.50%	-5.21%	-7.54%	-11.93%	-5.17%	-2.58%	-2.50%	0.01%	0.18%
ROIC Less NNEP Spread (ROIC-NNEP)	-29.69%	-26.04%	-13.63%	-15.39%	-17.42%	-18.25%	-7.21%	-8.95%	-3.04%	-4.51%
Return on Net Nonoperating Assets (RNNOA)	-0.89%	-1.32%	-1.10%	-1.50%	-2.03%	-2.12%	-0.99%	-1.15%	-0.41%	-0.53%
Return on Equity (ROE)	-7.36%	-8.82%	-6.32%	-9.04%	-13.96%	-7.28%	-3.58%	-3.65%	-0.41%	-0.35%
Cash Return on Invested Capital (CROIC)	0.00%	-14.27%	-10.99%	-8.71%	-8.86%	-7.29%	-6.55%	-2.99%	0.50%	2.80%
Operating Return on Assets (OROA)	-7.36%	-8.87%	-5.80%	-8.37%	-13.33%	-5.76%	-2.55%	-2.90%	0.01%	0.09%
Return on Assets (ROA)	-7.33%	-8.53%	-5.99%	-8.12%	-11.33%	-7.90%	-3.63%	-4.02%	-1.07%	-1.29%
Return on Common Equity (ROCE)	-7.36%	-8.82%	-6.32%	-9.04%	-13.96%	-7.28%	-3.58%	-3.65%	-0.41%	-0.35%
Return on Equity Simple (ROE_SIMPLE)	-18.28%	0.00%	-12.46%	-10.99%	-12.92%	0.00%	-12.11%	-10.55%	-6.63%	0.00%
Net Operating Profit after Tax (NOPAT)	-27	-32	-24	-34	-52	-23	-12	-11	0.03	0.74
NOPAT Margin	-12.50%	-14.04%	-9.45%	-13.06%	-19.80%	-8.05%	-3.91%	-3.57%	0.01%	0.23%
Net Nonoperating Expense Percent (NNEP)	23.22%	18.54%	8.42%	7.85%	5.49%	13.08%	4.63%	6.44%	3.04%	4.69%
Return On Investment Capital (ROIC_SIMPLE)	-	-1.83%	-	-	-	-1.32%	-	-	-	0.04%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	109.63%	-159.59%	105.95%	111.13%	120.82%	-164.97%	98.07%	99.15%	95.15%	-165.55%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	117.85%	120.06%	113.50%	118.65%	128.28%	111.50%	105.58%	105.11%	99.99%	99.67%
Earnings before Interest and Taxes (EBIT)	-38	-49	-33	-47	-72	-33	-15	-17	0.03	0.52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-20	-29	-14	-27	-52	-10	8.16	2.22	16	16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.63	1.22	1.86	2.30	1.78	2.07	1.64	1.31	1.86	1.95
Price to Tangible Book Value (P/TBV)	269.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.04	2.16	3.08	3.59	2.59	2.81	2.13	1.62	2.22	2.25
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.58	1.21	1.77	2.16	1.68	1.94	1.55	1.27	1.77	1.87
Enterprise Value to Revenue (EV/Rev)	3.20	2.31	3.26	3.77	2.80	3.01	2.34	1.79	2.37	2.35
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	179.85	70.91
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	55.21	37.69	71.32	108.62	1,255.75	0.00	0.00	151.76	46.28	27.46
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	344.88	65.56
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.15	0.16	0.16	0.17	0.18	0.20	0.20	0.20	0.20	0.19
Long-Term Debt to Equity	0.14	0.15	0.15	0.17	0.17	0.20	0.20	0.20	0.19	0.19
Financial Leverage	0.03	0.05	0.08	0.10	0.12	0.12	0.14	0.13	0.14	0.12
Leverage Ratio	1.27	1.34	1.35	1.37	1.39	1.45	1.45	1.47	1.48	1.47
Compound Leverage Factor	1.41	1.48	1.56	1.52	1.50	1.70	2.03	1.98	-257.11	-25.10
Debt to Total Capital	12.70%	13.69%	13.65%	14.78%	15.03%	16.80%	16.59%	16.53%	16.38%	16.21%
Short-Term Debt to Total Capital	0.62%	0.90%	0.76%	0.60%	0.52%	0.48%	0.26%	0.22%	0.15%	0.00%
Long-Term Debt to Total Capital	12.09%	12.79%	12.89%	14.18%	14.50%	16.32%	16.33%	16.31%	16.24%	16.21%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	87.30%	86.31%	86.35%	85.22%	84.97%	83.20%	83.41%	83.47%	83.62%	83.79%
Debt to EBITDA	-1.04	-1.70	-2.25	-2.91	-2.11	-2.81	-3.51	-5.44	17.72	6.74
Net Debt to EBITDA	-0.62	-0.93	-1.61	-2.02	-1.76	-2.04	-2.90	-3.77	11.26	3.01
Long-Term Debt to EBITDA	-0.99	-1.59	-2.13	-2.79	-2.04	-2.73	-3.45	-5.37	17.57	6.74
Debt to NOPAT	-1.15	-1.64	-1.90	-2.21	-1.81	-2.18	-2.36	-2.90	-6.19	-12.64
Net Debt to NOPAT	-0.68	-0.90	-1.35	-1.53	-1.51	-1.58	-1.95	-2.01	-3.94	-5.66
Long-Term Debt to NOPAT	-1.09	-1.53	-1.79	-2.12	-1.75	-2.12	-2.33	-2.87	-6.14	-12.64
Altman Z-Score	3.40	1.69	2.56	3.03	2.07	2.57	2.08	1.65	2.47	2.62
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.25	1.33	1.17	1.32	1.10	1.11	1.18	1.22	1.32	1.37
Quick Ratio	1.81	1.19	1.03	1.11	0.80	1.01	1.09	1.12	1.20	1.25
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-187	-115	-79	-61	-58	-10	-0.76	37	54	68
Operating Cash Flow to CapEx	37.96%	345.90%	-102.08%	-3.75%	-258.83%	147.14%	-427.86%	862.23%	449.85%	988.99%
Free Cash Flow to Firm to Interest Expense	-44.64	-22.21	-15.58	-12.00	-10.55	-1.82	-0.13	6.36	9.94	7.22
Operating Cash Flow to Interest Expense	1.37	6.95	-1.55	-0.08	-4.63	3.04	-3.70	7.57	4.20	6.63
Operating Cash Flow Less CapEx to Interest Expense	-2.24	4.94	-3.07	-2.35	-6.42	0.97	-4.56	6.69	3.26	5.96
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.42	0.42	0.44	0.46	0.48	0.49	0.52	0.54	0.56	0.59
Accounts Receivable Turnover	8.95	9.72	8.52	8.66	7.64	9.33	7.50	8.00	7.83	9.73
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	5.32	4.96	4.99	5.00	5.24	5.52	5.87	6.27	6.70	7.06
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	40.80	37.57	42.84	42.16	47.79	39.12	48.67	45.62	46.59	37.52
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	40.80	37.57	42.84	42.16	47.79	39.12	48.67	45.62	46.59	37.52
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,664	1,651	1,675	1,675	1,670	1,639	1,664	1,626	1,616	1,572
Invested Capital Turnover	0.52	0.53	0.55	0.58	0.60	0.64	0.66	0.70	0.73	0.78
Increase / (Decrease) in Invested Capital	160	83	55	28	5.75	-12	-11	-48	-54	-67
Enterprise Value (EV)	2,623	1,990	2,966	3,620	2,812	3,174	2,584	2,073	2,857	2,945
Market Capitalization	2,490	1,857	2,796	3,440	2,597	2,964	2,349	1,877	2,678	2,820
Book Value per Share	$4.07	$4.04	$4.00	$3.97	$3.85	$3.77	$3.75	$3.74	$3.76	$3.78
Tangible Book Value per Share	$0.02	($0.05)	($0.11)	($0.11)	($0.19)	($0.23)	($0.19)	($0.17)	($0.13)	($0.10)
Total Capital	1,754	1,760	1,743	1,754	1,712	1,717	1,713	1,713	1,719	1,726
Total Debt	223	241	238	259	257	288	284	283	282	280
Total Long-Term Debt	212	225	225	249	248	280	280	279	279	280
Net Debt	133	132	170	180	215	210	235	196	179	125
Capital Expenditures (CapEx)	15	10	7.73	12	9.80	11	5.10	5.11	5.05	6.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	61	-36	-24	-12	-10	-48	-8.34	-33	-31	-71
Debt-free Net Working Capital (DFNWC)	151	73	45	68	32	31	41	54	72	84
Net Working Capital (NWC)	140	57	31	57	23	23	37	50	70	84
Net Nonoperating Expense (NNE)	11	14	10	12	9.53	22	9.36	12	5.99	7.85
Net Nonoperating Obligations (NNO)	133	132	170	180	215	210	235	196	179	125
Total Depreciation and Amortization (D&A)	18	19	20	20	20	23	23	19	16	15
Debt-free, Cash-free Net Working Capital to Revenue	7.41%	-4.13%	-2.60%	-1.26%	-1.02%	-4.53%	-0.76%	-2.86%	-2.54%	-5.67%
Debt-free Net Working Capital to Revenue	18.43%	8.50%	4.91%	7.04%	3.22%	2.94%	3.73%	4.66%	5.97%	6.68%
Net Working Capital to Revenue	17.11%	6.66%	3.45%	5.95%	2.33%	2.17%	3.32%	4.33%	5.76%	6.68%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	357.52K	355.28M	360.90K	363.16K	372.48K	367.46M	376.33M	379.43M	380.36M	379.15M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	375.99M	355.28M	360.90K	363.16K	372.48K	367.46M	376.33M	379.43M	380.36M	379.15M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	375.99M	376.37M	376.76M	378.01M	378.61M	380.69M	382.29M	382.62M	382.64M	384.55M
Normalized Net Operating Profit after Tax (NOPAT)	-27	-32	-24	-34	-52	-23	-12	-11	0.03	0.74
Normalized NOPAT Margin	-12.50%	-14.04%	-9.45%	-13.06%	-19.80%	-8.05%	-3.91%	-3.57%	0.01%	0.23%
Pre Tax Income Margin	-19.40%	-23.42%	-15.15%	-20.04%	-29.66%	-13.65%	-6.90%	-7.24%	-1.72%	-2.73%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-9.08	-9.40	-6.52	-9.16	-13.24	-5.93	-2.51	-2.88	0.01	0.06
NOPAT to Interest Expense	-6.49	-6.24	-4.69	-6.62	-9.50	-4.08	-1.99	-1.92	0.01	0.08
EBIT Less CapEx to Interest Expense	-12.68	-11.41	-8.04	-11.42	-15.02	-7.99	-3.38	-3.76	-0.93	-0.62
NOPAT Less CapEx to Interest Expense	-10.09	-8.25	-6.20	-8.88	-11.29	-6.15	-2.85	-2.79	-0.93	-0.59
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About LifeStance Health Group's Financials

When does LifeStance Health Group's fiscal year end?

According to the most recent income statement we have on file, LifeStance Health Group's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has LifeStance Health Group's net income changed over the last 4 years?

Over the last 4 years, LifeStance Health Group's net income changed from $5.67 million in 2019 to -$57.44 million in 2024, a change of -1,113.3%.

What is LifeStance Health Group's operating income?

LifeStance Health Group's total operating income in 2024 was -$31.61 million, based on the following breakdown:

Total Gross Profit: $1.25 billion
Total Operating Expenses: $1.28 billion

How has LifeStance Health Group revenue changed over the last 4 years?

Over the last 4 years, LifeStance Health Group's total revenue changed from $212.52 million in 2019 to $1.25 billion in 2024, a change of 488.6%.

How much debt does LifeStance Health Group have?

LifeStance Health Group's total liabilities were at $672.01 million at the end of 2024, a 1.3% decrease from 2023, and a 25.2% increase since 2020.

How much cash does LifeStance Health Group have?

In the past 4 years, LifeStance Health Group's cash and equivalents has ranged from $18.83 million in 2020 to $154.57 million in 2024, and is currently $154.57 million as of their latest financial filing in 2024.

How has LifeStance Health Group's book value per share changed over the last 4 years?

Over the last 4 years, LifeStance Health Group's book value per share changed from 0.00 in 2019 to 3.78 in 2024, a change of 378.0%.

Remove Ads

Related Companies

This page (NASDAQ:LFST) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LifeStance Health Group (LFST) Financials

Frequently Asked Questions About LifeStance Health Group's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LifeStance Health Group (LFST) Financials

Annual Income Statements for LifeStance Health Group

Quarterly Income Statements for LifeStance Health Group

Annual Cash Flow Statements for LifeStance Health Group

Quarterly Cash Flow Statements for LifeStance Health Group

Annual Balance Sheets for LifeStance Health Group

Quarterly Balance Sheets for LifeStance Health Group

Annual Metrics and Ratios for LifeStance Health Group

Quarterly Metrics and Ratios for LifeStance Health Group

Frequently Asked Questions About LifeStance Health Group's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools